<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02296723</url>
  </required_header>
  <id_info>
    <org_study_id>570-10</org_study_id>
    <nct_id>NCT02296723</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fed Condition</brief_title>
  <official_title>Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Cross Over, Single Dose, Oral Bioequivalence Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fed Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the Valganciclovir Hydrochloride Tablets 450 mg of Dr. Reddy's&#xD;
      Laboratories Limited, India and Valcyte® (Valganciclovir HCl) tablets 450 mg of Genentech USA&#xD;
      Inc., Group of Roche, South San Francisco in healthy, adult, human subjects under Fed&#xD;
      conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, balanced, randomized, two-treatment, two-period, two-sequence, cross over, single&#xD;
      dose, oral bioequivalence study of Valganciclovir Hydrochloride Tablets 450 mg under Fed&#xD;
      conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>0.00 and at 0.167, 0.333, 0.50, 0.667, 0.833, 1.00, 1.25, 1.50, 1.75, 2.00, 2.333, 2.667, 3.00, 3.333, 3.667, 4.00, 6.00, 8.00, 10.00, 12.00, 16.00 and 24.00 hours post dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Valganciclovir Hydrochloride Tablets 450 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valganciclovir Hydrochloride Tablets 450 mg of Dr. Reddys Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valcyte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valcyte® 450 mg tablets of Genentech USA Inc., Sanfrancisco</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir Hydrochloride</intervention_name>
    <description>Valganciclovir Hydrochloride Tablets 450 mg</description>
    <arm_group_label>Valcyte</arm_group_label>
    <arm_group_label>Valganciclovir Hydrochloride Tablets 450 mg</arm_group_label>
    <other_name>Valcyte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, adult, human volunteers between 18 to 55 years of age (both inclusive) living&#xD;
             in and around Ahmedabad city or western part of lndia&#xD;
&#xD;
          -  Having a Body Mass Index (BMD between 18.5 - 24.9 (both inclusive), calculated as&#xD;
             weight in kg / height in meter2&#xD;
&#xD;
          -  Not having any significant disease in medical history or clinically significant&#xD;
             abnormal findings during screening, medical history, physical examination, laboratory&#xD;
             evaluations, L2- lead ECG and X-ray chest (postero-anterior view) recordings&#xD;
&#xD;
          -  Able to understand and comply with the study procedures, in the opinion of the&#xD;
             principal investigator&#xD;
&#xD;
          -  Able to give voluntary written informed consent for participation in the trial&#xD;
&#xD;
          -  In case of Male subjects:&#xD;
&#xD;
               -  Willing to practice an acceptable barrier contraception method of birth control&#xD;
                  for the entire duration of the study and at least for 90 days after the last dose&#xD;
                  administration, and in case of an accidental pregnancy of their spouse should be&#xD;
                  willing to abort the pregnancy&#xD;
&#xD;
        Or&#xD;
&#xD;
          -  Surgically sterile who have undergone vasectomy&#xD;
&#xD;
             - In case of female subjects:&#xD;
&#xD;
          -  Surgically sterilized (Bilateral tubal ligation, bilateral oophorectomy, or&#xD;
             hysterectomy) at least 6 months prior to study participation Or&#xD;
&#xD;
          -  If of child bearing potential is willing to use a suitable and effective double&#xD;
             barrier contraceptive method or intra uterine device of birth control or abstinence&#xD;
             for the entire during of the study and at least 90 days after the last study drug&#xD;
             administration and in case of an accidental pregnancy should be willing to abort the&#xD;
             pregnancy Or&#xD;
&#xD;
          -  Postmenopausal women: Women who are postmenopausal for at least 1 year having Follicle&#xD;
             stimulating Hormone (FSH) level and serum estradiol level (without hormone replacement&#xD;
             therapy) within specified limit suggestive of menopausal state, having normal&#xD;
             bilateral mammogram and normal ultrasound abdomen and pelvis And&#xD;
&#xD;
          -  Pregnancy test must be negative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or idiosyncratic reaction to Valganciclovir and/or ganciclovir&#xD;
             or any of the excipients or any related drug&#xD;
&#xD;
          -  History or presence of any disease or condition which might compromise the&#xD;
             haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular,&#xD;
             immunological, dermatological, gastrointestinal or any other body system&#xD;
&#xD;
          -  Ingestion of a medicine at any time within 14 days before dosing in Period I In any&#xD;
             such case subject selection will be at the discretion of the Principal Investigator.&#xD;
&#xD;
          -  Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or&#xD;
             NSAID induced urticaria&#xD;
&#xD;
          -  A recent history of harmful use of alcohol(less than 2 years), i,e. alcohol&#xD;
             consumption of more than 14 standard drinks per week for men and more than 7 standard&#xD;
             drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of&#xD;
             wine or 45 ml of 40o/o distilled spirits, such as rum, whisky, brandy etc) or&#xD;
             consumption of alcohol or alcoholic products within 48 hours prior to receiving study&#xD;
             medicine&#xD;
&#xD;
          -  Smokers, who smoke 10 or more than 10 cigarettes/day or inability to abstain from&#xD;
             smoking during the study&#xD;
&#xD;
          -  The presence of clinically significant abnormal laboratory values during screening&#xD;
&#xD;
          -  Use of any recreational drugs or history of drug addiction or testing positive in&#xD;
             prestudy drug scans&#xD;
&#xD;
          -  History or presence of psychiatric disorders&#xD;
&#xD;
          -  A history of difficulty in donating blood&#xD;
&#xD;
          -  Donation of blood (1 unit or 350 mL) or receipt of an investigational medicinal&#xD;
             product or participation in a drug research study within a period of 90 days prior to&#xD;
             the first dose of study medication. Elimination half-life of the study drug should be&#xD;
             taken into consideration for inclusion of the subject in the study Note: In case the&#xD;
             blood loss is &lt; 200 mL; subject may be dosed 60 days after blood donation or last&#xD;
             sample of the previous study&#xD;
&#xD;
          -  A positive hepatitis screen including hepatitis B surface antigen and HCV (Hepatitis C&#xD;
             Virus) antibodies&#xD;
&#xD;
          -  A positive test result for HIV antibody&#xD;
&#xD;
          -  An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to&#xD;
             receiving the study medicine. In any such case subject selection will be at the&#xD;
             discretion of the Principal Investigator&#xD;
&#xD;
          -  Consumption of grape fruit or grape fruit products within 48 hours prior to dosing.&#xD;
&#xD;
          -  Nursing mothers (females)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Pankaj Kumar Jha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lambda Therapeutic Research Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lambda Therapeutic Research Ltd</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <zip>380 061</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>November 19, 2014</last_update_submitted>
  <last_update_submitted_qc>November 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

